Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

The biology and therapeutic management of melanoma brain metastases

(2018) Daniel Abate-Daga et al.   BIOCHEMICAL PHARMACOLOGY

Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs

(2018) Bodo Haas et al.   Cancer Cell International

Cutaneous melanoma: From pathogenesis to therapy (Review)

(2018) Giulia Leonardi et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Buparlisib is a brain penetrable pan-PI3K inhibitor

(2018) Mark C. de Gooijer et al.   Scientific Reports

The Mechanics of Single Cell and Collective Migration of Tumor Cells

(2017) Marianne Lintz et al.   JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME

MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation

(2017) Ying Zhao et al.   ONCOLOGY REPORTS

Phenotype characterization of human melanoma cells resistant to dabrafenib

(2017) Fabiola Gilda Cordaro et al.   ONCOLOGY REPORTS

Modeling Physiological Events in 2D vs. 3D Cell Culture

(2017) Kayla Duval et al.   PHYSIOLOGY

Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications

(2017) Grant M. Fischer et al.   Pigment Cell & Melanoma Research

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo

(2016) H. Niessner et al.   CLINICAL CANCER RESEARCH

Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer

(2016) Beatrice Bissig-Choisat et al.   JOURNAL OF HEPATOLOGY

Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma

(2016) Allison Isola et al.   Cancers

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma

(2016) Maria-Carmela Speranza et al.   Scientific Reports

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Melanoma brain metastasis is independent of lactate dehydrogenase A expression

(2015) Terje Sundstrøm et al.   NEURO-ONCOLOGY

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

(2015) P. K. Brastianos et al.   Cancer Discovery

Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma

(2015) Kian Ngiap Chua et al.   Oncotarget

The MAPK pathway as an apoptosis enhancer in melanoma

(2015) Johannes M. Haydn et al.   Oncotarget

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

(2014) Yuichi Ando et al.   CANCER SCIENCE

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways

(2014) Inderjit Daphu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

(2014) Georgina V. Long et al.   Nature Communications

The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma

(2013) M. Chatterjee et al.   HAEMATOLOGICA

A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma

(2013) TAKESHI YAMADA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

The Role of the PI3K-AKT Pathway in Melanoma

(2012) Michael A. Davies   CANCER JOURNAL

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

(2012) S. M. Brachmann et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines

(2012) Brenden Chen et al.   PLoS One

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy

(2011) Qian Huang et al.   NATURE MEDICINE

The biology of brain metastases—translation to new therapies

(2011) April F. Eichler et al.   Nature Reviews Clinical Oncology

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways

(2008) Aisha Siddiqa et al.   BMC CANCER

Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide

(2008) Tobias Sinnberg et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY